These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1234 related items for PubMed ID: 25539810

  • 1. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.
    J Immunol; 2015 Feb 01; 194(3):950-9. PubMed ID: 25539810
    [Abstract] [Full Text] [Related]

  • 2. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B, Pommey S, Smyth MJ, Stagg J.
    Clin Cancer Res; 2013 Oct 15; 19(20):5626-35. PubMed ID: 23983257
    [Abstract] [Full Text] [Related]

  • 3. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.
    Cancer Discov; 2016 Aug 15; 6(8):827-37. PubMed ID: 27301722
    [Abstract] [Full Text] [Related]

  • 4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.
    Clin Cancer Res; 2017 Oct 15; 23(20):6165-6177. PubMed ID: 28855348
    [Abstract] [Full Text] [Related]

  • 5. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.
    Cancer Immunol Res; 2016 Feb 15; 4(2):124-35. PubMed ID: 26546453
    [Abstract] [Full Text] [Related]

  • 6. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA, Callahan MK, Wolchok JD.
    J Clin Oncol; 2015 Jun 10; 33(17):1974-82. PubMed ID: 25605845
    [Abstract] [Full Text] [Related]

  • 7. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP.
    Cell; 2017 Sep 07; 170(6):1120-1133.e17. PubMed ID: 28803728
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD.
    Breast Cancer Res; 2016 May 11; 18(1):50. PubMed ID: 27169467
    [Abstract] [Full Text] [Related]

  • 10. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.
    Eur Urol; 2015 Aug 11; 68(2):267-79. PubMed ID: 25824720
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, Bailey D, Regan SN, Ivanova E, Ferrante C, English JM, Khosla A, Beck AH, Rytlewski JA, Sanders C, Laquerre S, Bittinger MA, Kirschmeier PT, Packman K, Janne PA, Moy C, Wong KK, Verona RI, Lorenzi MV.
    Cancer Immunol Res; 2019 Sep 11; 7(9):1457-1471. PubMed ID: 31331945
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL, Page DB.
    Clin Adv Hematol Oncol; 2016 Nov 11; 14(11):922-933. PubMed ID: 27930644
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.
    Cancer Cell; 2019 Feb 11; 35(2):238-255.e6. PubMed ID: 30753825
    [Abstract] [Full Text] [Related]

  • 16. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, Blank CU, Verbrugge I.
    Cancer Immunol Immunother; 2016 Jun 11; 65(6):753-63. PubMed ID: 27160390
    [Abstract] [Full Text] [Related]

  • 17. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP.
    Proc Natl Acad Sci U S A; 2019 Nov 05; 116(45):22699-22709. PubMed ID: 31636208
    [Abstract] [Full Text] [Related]

  • 18. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
    Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J.
    Bull Cancer; 2018 Nov 05; 105(11):1033-1041. PubMed ID: 30244981
    [Abstract] [Full Text] [Related]

  • 19. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.
    Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, Nookala S, Sierra G, Curran MA, Sastry KJ.
    J Immunother Cancer; 2019 Sep 18; 7(1):252. PubMed ID: 31533840
    [Abstract] [Full Text] [Related]

  • 20. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY, Chen YL, Lin HW, Chiang YC, Chang CF, Tai YJ, Chen CA, Sun WZ, Chien CL, Cheng WF.
    Cancer Lett; 2019 Mar 01; 444():20-34. PubMed ID: 30543813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.